Kindstar Globalgene Technology Inc

The company's capital structure is characterized by a lack of detailed balance-sheet inputs, which prevents a comprehensive assessment of its liquidity position. The shares outstanding for both basic and diluted scenarios are identical at 1,034,245,964, indicating no dilution from stock options or convertible securities at this time. However, the absence of liquidity metrics and the lack of going-concern language in source documents suggest that the company's short-term financial health cannot be fully evaluated.

In terms of profitability, the company reported a last actual EPS of 0.09 CNY and a last actual revenue of 1,386,591,000 CNY. These figures provide a baseline for assessing the company's performance, but without industry-specific metrics or cohort medians, a direct comparison to industry standards is not possible. The company's return on invested capital (ROIC) and other profitability ratios are not available, which limits the ability to evaluate its efficiency in generating returns from its investments.

The company's revenue is primarily derived from its pharmaceutical products, with a focus on oncology and autoimmune diseases. However, the input data does not provide specific details on revenue concentration by segment or geography, making it difficult to assess the company's exposure to particular markets or product lines.

The company's growth trajectory is not clearly defined in the available data. The input does not include forward-looking revenue projections or historical growth rates, which are necessary to evaluate the company's future performance. The absence of detailed financial history and outlook data limits the ability to make informed predictions about the company's revenue growth.

The company's risk profile is marked by a low dilution potential, as the shares outstanding for both basic and diluted scenarios are the same. However, the lack of liquidity metrics and the absence of going-concern language in source documents indicate that the company's financial stability is not fully transparent. The risk assessment also notes that liquidity risk could not be assessed due to the lack of balance-sheet inputs.

Recent events and filings do not provide specific details on the company's operations or financial status. The input data does not include recent earnings calls, investor presentations, or other disclosures that could provide insight into the company's strategic direction or operational performance.

Revenue ¥933.6M, +0,7% YoY; Operating income +43,5% YoY.

• ▍Revenue ¥933.6M, +0,7% YoY
• ▍Operating income +43,5% YoY
• ▍Net income −7,6% YoY
• ▍Free cash flow +86,6% YoY
• ▍Net margin -6.3%

Revenue ¥927.6M, −4,1% YoY; Operating income −187,8% YoY.

• ▍Revenue ¥927.6M, −4,1% YoY
• ▍Operating income −187,8% YoY
• ▍Net income −232,2% YoY
• ▍Free cash flow −132,1% YoY
• ▍Net margin -5.9%